Senores Pharmaceuticals Ltd
Senores Pharma: No Deviation in Rs. 95 Crore Preferential Issue Fund Use (Q1 FY27)
FUNDRAISE
● No Immediate Change
LOW RISK
📅 Filed on BSE: 27 Jul 2026, 05:53 PM IST · BSE ID: 709d9ebb-103e-497c-86a3-d68be995b567
View Original BSE Filing (PDF)
💡
In Simple Terms
The company confirmed it used its recent Rs. 95 crore fundraise exactly as planned and approved.
🤖 AI Summary
- Senores Pharma confirms no deviation in utilization of Rs. 95,00,40,000 raised via preferential issue.
- Funds were raised through 11,70,000 convertible equity warrants in March 2026.
- The report covers the quarter ended June 30, 2026, as per SEBI LODR regulations.
- Audit Committee and Board of Directors reviewed and approved the statement on July 27, 2026.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Amount Raised via Preferential Issue
Rs. 95,00,40,000
Number of Convertible Equity Warrants
11,70,000
Exercise Price per Warrant
Rs. 812/-
Quarterly Fund Utilization Report Period
June 30, 2026
🏢 How This Affects the Company
This filing confirms the company's adherence to its stated fundraising objectives, reinforcing its financial discipline.
It assures stakeholders that the Rs. 95,00,40,000 raised is being deployed for the intended purposes, supporting the company's financial plans.
This filing mitigates concerns regarding potential mismanagement or diversion of funds raised through the preferential issue.
👥 What This Means For Shareholders
✅
Action Required
No action is required from shareholders regarding this filing.
👤
Who Is Affected
All shareholders are affected as this filing pertains to the responsible utilization of company funds raised from them.
🔍
Management Signal
This filing signals management's commitment to transparency and adherence to regulatory requirements concerning fund utilization.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Next quarterly fund utilization statement for Q2 FY27.
Company's financial results for Q2 FY27.
Progress on business objectives funded by the preferential issue.
LOW RISK
Filing is a routine compliance report confirming no deviation in fund utilization.
💡 Investor Takeaway
Senores Pharmaceuticals confirms no deviation in utilizing Rs. 95,00,40,000 raised from warrants in March 2026, for the quarter ending June 30, 2026.
⚖️ Strengths & Concerns
✅ Positives
- No deviation in utilization of Rs. 95,00,40,000 raised through preferential issue of warrants.
- Successful deployment of funds towards stated objectives confirmed by Audit Committee and Board.
📅 Company Track Record
In March 2026, Senores Pharma allotted 11,70,000 warrants at Rs. 812 each, raising Rs. 95 crore. Promoter stake rose to 25.26% upon conversion.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What was the total amount raised by Senores Pharmaceuticals through the preferential issue of warrants?
Senores Pharmaceuticals Limited raised Rs. 95,00,40,000 through the preferential issue of 11,70,000 convertible equity warrants.
What period does the latest fund utilization statement from Senores Pharma cover?
The statement of deviation or variation in utilization of funds covers the quarter ended June 30, 2026.
Has Senores Pharmaceuticals reported any deviation in the utilization of funds from its preferential issue?
No, Senores Pharmaceuticals Limited has confirmed that there has been no deviation or variation in the utilization of funds raised through the preferential issue of convertible equity warrants.
When were the funds raised by Senores Pharmaceuticals through the preferential issue?
The funds were raised on March 28, 2026.
Questions based on this BSE filing only. For information purposes.